» Articles » PMID: 34599147

Alterations of Kynurenine Pathway in Alcohol Use Disorder and Abstinence: a Link with Gut Microbiota, Peripheral Inflammation and Psychological Symptoms

Overview
Date 2021 Oct 2
PMID 34599147
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

The gut-brain communication is mostly driven by the immune, metabolic and neural pathways which remained poorly explored in patients with alcohol use disorder (AUD). The metabolites arising from the tryptophan-kynurenine pathway have gained considerable attention since they are at the interface between intestinal bacteria, host immune response and brain functions. This study described the circulating levels of kynurenine metabolites in AUD patients, at the onset (T1) and end (T2) of a 3-week detoxification program, and tested correlations between those metabolites and inflammatory markers, the gut microbiota and the psychological symptoms. Increased concentration of the neurotoxic metabolite quinolinic acid (QUIN) and decreased levels of the neuroprotector metabolite kynurenic acid (KYNA) which both modulate glutamatergic neurotransmission were observed in AUD patients, particularly at T2. The inflammatory marker hsCRP was associated with several metabolic ratios of the kynurenine pathway. Tryptophan, KYNA and QUIN were correlated with depression, alcohol craving and reaction time, respectively. Analysis of gut microbiota revealed that bacteria known as short-chain fatty acid producers, as well as bacterial metabolites including butyrate and medium-chain fatty acids were associated with some metabolites of the tryptophan-kynurenine pathway. Targeting the glutamatergic neurotransmission through the modulation of the kynurenine pathway, by manipulating the gut microbiota, might represent an interesting alternative for modulating alcohol-related behavior.

Citing Articles

Alcohol Use Disorder and the Gut-Brain Axis: A Narrative Review of the Role of Gut Microbiota and Implications for Treatment.

Shukla S, Hsu C Microorganisms. 2025; 13(1).

PMID: 39858835 PMC: 11767426. DOI: 10.3390/microorganisms13010067.


Redefining Roles: A Paradigm Shift in Tryptophan-Kynurenine Metabolism for Innovative Clinical Applications.

Tanaka M, Szabo A, Vecsei L Int J Mol Sci. 2024; 25(23).

PMID: 39684480 PMC: 11640972. DOI: 10.3390/ijms252312767.


Mapping the relationship between alcohol use disorder and gut microbiota: a 20-year bibliometric study.

Xiang A, Chang Y, Shi L, Zhou X Front Microbiol. 2024; 15:1457969.

PMID: 39624719 PMC: 11609174. DOI: 10.3389/fmicb.2024.1457969.


Impact of Substance Use Disorder on Tryptophan Metabolism Through the Kynurenine Pathway: A Narrative Review.

Contella L, Farrell C, Boccuto L, Litwin A, Snyder M Metabolites. 2024; 14(11).

PMID: 39590847 PMC: 11597030. DOI: 10.3390/metabo14110611.


Region-Specific Gene Expression Changes Associated with Oleoylethanolamide-Induced Attenuation of Alcohol Self-Administration.

Gonzalez-Portilla M, Montagud-Romero S, Mellado S, Rodriguez de Fonseca F, Pascual M, Rodriguez-Arias M Int J Mol Sci. 2024; 25(16).

PMID: 39201687 PMC: 11354326. DOI: 10.3390/ijms25169002.


References
1.
Dubinkina V, Tyakht A, Odintsova V, Yarygin K, Kovarsky B, Pavlenko A . Links of gut microbiota composition with alcohol dependence syndrome and alcoholic liver disease. Microbiome. 2017; 5(1):141. PMC: 5645934. DOI: 10.1186/s40168-017-0359-2. View

2.
Bedarf J, Hildebrand F, Coelho L, Sunagawa S, Bahram M, Goeser F . Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naïve Parkinson's disease patients. Genome Med. 2017; 9(1):39. PMC: 5408370. DOI: 10.1186/s13073-017-0428-y. View

3.
Rohart F, Gautier B, Singh A, Le Cao K . mixOmics: An R package for 'omics feature selection and multiple data integration. PLoS Comput Biol. 2017; 13(11):e1005752. PMC: 5687754. DOI: 10.1371/journal.pcbi.1005752. View

4.
Fujigaki H, Yamamoto Y, Saito K . L-Tryptophan-kynurenine pathway enzymes are therapeutic target for neuropsychiatric diseases: Focus on cell type differences. Neuropharmacology. 2016; 112(Pt B):264-274. DOI: 10.1016/j.neuropharm.2016.01.011. View

5.
Vecsei L, Szalardy L, Fulop F, Toldi J . Kynurenines in the CNS: recent advances and new questions. Nat Rev Drug Discov. 2012; 12(1):64-82. DOI: 10.1038/nrd3793. View